Pharmacological Profile

Active Ingredients: 2.5% Lidocaine HCl + 2.5% Prilocaine (EMLA-equivalent O/W emulsion). Hepatic metabolism primarily via CYP3A4; renal excretion.

Delivery System: Micro-emulsified phase (<5μm particle size) combined with optimized 15,000 cps viscosity limits lateral migration during application. Penetrates up to 5mm into the dermal-epidermal junction within 60 minutes under occlusion.

Clinical Efficacy Metrics

Onset Time: 60-90 minutes (occlusive state required).

Analgesic Duration: 120-180 minutes post-removal.

VAS Scale Variance: Average 4.2-point reduction.

Absorption Multiplier: 300% dermal uptake increase via film occlusion.

Formulation Specifications

pH Range: 5.5 – 6.5 (Dermal barrier matched).

Microbial Sterility: USP 61 Compliant (<100 CFU/g).

Application Density: 0.7g/cm² optimal coverage ratio.

Thermal Stability: 36 months baseline @ 25°C.

Safety Parameters, Dosage Limits & Packaging

Maximum Clinical Dosage: 30g per single application session. Surface area exposure must not exceed 400cm² to mitigate risk of systemic toxicity.

Absolute Contraindications: Strictly prohibited for mucosal contact, intraocular exposure, or application on compromised/ablated skin barriers. Contraindicated for patients exhibiting documented hypersensitivity to amide-type local anesthetics or cetyl alcohol components. Not evaluated for pediatric efficacy (patients <12 years).

Packaging Compliance: Housed in a 500g High-Density Polyethylene (HDPE) medical-grade jar. Secured via heat-induction tamper-evident inner foil seal. All units are individually batch-tracked utilizing GS1-compliant lot identification formats.